Last reviewed · How we verify

NCT05703386

Imaging the Pathogenesis of Cerebral Small Vessel Disease

Recruiting now Last updated 3 March 2026
What this trial tests

trial in Ischemic Stroke in 50 participants. Currently enrolling.

Timeline
8 November 2022
Primary endpoint
31 March 2027
31 March 2027

Quick facts

Lead sponsorJohns Hopkins University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date8 November 2022
Primary completion31 March 2027
Estimated completion31 March 2027
Sites1 location across United States

Conditions studied

Sponsor

Johns Hopkins University

Who can join

18 and older, any sex, with Ischemic Stroke or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05703386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing